CoChat

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Paz-Ares, Luis G., Luft, Alexander, Tafreshi, Ali, Gumus, Mahmut, Mazieres, Julien, Hermes, Barbara, Cay Senler, Filiz, Fülöp, Andrea, Rodriguez-Cid, Jeronimo, Sugawara, Shunichi, Cheng, Ying, Novello, Silvia, Halmos, Balazs, Shentu, Yue, Kowalski, Dariusz · 2018 · Journal of Clinical Oncology
Cited by 121

The DOI matches its Crossref record.

Abstract

105 Background: Pembro plus pemetrexed and carboplatin resulted in superior objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for untreated pts with non-sq NSCLC. Pembro is active in sq NSCLC, so combining with chemo is a rational next step. Methods: KEYNOTE-407 (NCT02775435) is a randomized, placebo-controlled, global study of 560 untreated pts with metastatic sq NSCLC with ECOG 0-1. Pts were stratified by type of taxane, PD-L1 (TPS <1% vs ≥1%), and site (East Asia vs other). Investigators chose taxane. Pts were randomized 1:1 to receive carboplatin 6 mg/mL/min and paclitaxel 200 mg/m2 every 3 weeks or nab-paclitaxel 100 mg/m2 weekly plus pembro or saline placebo for 4 cycles followed by pembro/placebo for a total of 35 treatments. Imaging is sent for blinded independent central review (BICR) per RECIST 1.1. The primary endpoints are PFS by BICR and OS in the intent-to-treat population. Alpha is strictly controlled at 0.025 one-sided; PFS and OS each have 0.01. A key secondary endpoint is ORR by BICR in about the first 200 pts randomized with 0.005 alpha. A second interim analysis will be performed on PFS and OS when approximately 332 PFS events will have occurred. The hazard ratio (target 0.7) will be estimated using a stratified Cox regression model. The arms will be compared with a stratified log-rank test. Enrollment completed at the end of 2017. Results: In the first interim analysis, the initial 204 pts were randomized 101 to pembro + chemo and 103 to chemo with median follow-up of 7.7 m (range 0.4, 13.9). Pts were 78% male, 48% < 65 y, and 28% ECOG PS 0. PD-L1 status was 35% TPS<1%. 32% used nab-paclitaxel. Per BICR pembro + chemo had an ORR of 58.4% compared to 35.0%, p-value 0.0004. Duration of response ≥6m was 65.8% for pembro + chemo and 45.6% for chemo by Kaplan-Meier estimates. Incidence grade ≥3 AEs was 64.4% for pembro + chemo and 74.5% for chemo. No new safety concerns were observed. Conclusions: Adding pembro almost doubled the ORR of chemo for pts with untreated metastatic sq NSCLC. Pembro + chemo has a tolerable safety profile. Results from a second interim analysis may be available prior to the meeting. Clinical trial information: NCT02775435.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.105

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 121

Metadata

Authors
Paz-Ares, L. G., Luft, A., Tafreshi, A., Gumus, M., Mazieres, J., Hermes, B., Cay Senler, F., Fülöp, A., Rodriguez-Cid, J., Sugawara, S., Cheng, Y., Novello, S., Halmos, B., Shentu, Y., & Kowalski, D.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
105-105
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2807431877
Cited by
121
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.105
The paper
Paz-Ares, L. G., Luft, A., Tafreshi, A., Gumus, M., Mazieres, J., Hermes, B., Cay Senler, F., Fülöp, A., Rodriguez-Cid, J., Sugawara, S., Cheng, Y., Novello, S., Halmos, B., Shentu, Y., & Kowalski, D. (2018). Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.